SEER-2

Recruiting
99 years or below
All
Phase N/A
2 participants needed
1 Location

Brief description of study

This study aims to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 19 May 2026. Study ID: 26-5841

Pre-Screener

Check if you are eligible Enter contact details Select a study center Select best time to contact

Have you been diagnosed with Neurotrophic Keratitis in either eye?

Preview complete

The prescreener preview is complete. You may now close the preview.

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center